Abstract 1520P
Background
In recent years, the use of both molecular targeting agents (MTAs) and immune-checkpoint inhibitors (ICIs) tend to occupy important positions in Systemic anticancer therapy (SACT). However, the effects of using MTAs and ICIs near the end of life (EOL) in patients with advanced cancer in SACT is unclear.
Methods
The primary endpoint of this study was to identify related factors during the last administration of SACT near EOL. The secondary endpoint was to analyze the relationship between EOL symptoms and EOL treatment details.
Results
In a multivariate analysis of the related factors within 14 days of death from the last administration of SACT, ECOG-PS (ORs 19.404) was significantly related to the number of metastatic sites (ORs 3.003). Related factors within 30 days of the death, ECOG-PS (ORs 6.211), primary cancer site of upper GI cancers (ORs 2.574), and MTAs (ORs 3.637) were significantly related factors, while ICIs (ORs 2.351) was not. The median survival time (MST) of patients with PS 3-4 was 29 days, while that of patients with both PS 0-2 was 76 days. The MST of patients with upper GI cancers was 76 days, while that of patients with other cancers was 95 days. The MST of patients with MTA was 59 days, while that of patients without MTA was 93 days. The prevalence rate of nausea and vomiting in patients with MTAs was 2.3%, which was significantly lower than that of patients without it (9.6%). The prevalence rate of delirium, fatigue, and the mean dose of opioids in patients with ICIs was 21.1%, 10.5% and 43.98 mg/day. ECOG-PS, primary cancer site, and MTAs use were significantly associated with SACT near EOL.
Conclusions
Information on these factors may aid clinical decision-making in referral to palliative care institutes, particularly in patients with poor prognosis, upper GI cancers, and MTAs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest..